登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603998 证券简称：方盛制药 公告编号：2025-086 湖南方盛制药股份有限公司 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年10月17日（星期五）至10月23日（星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱fs88997135@126.com、603998@fangsheng.com.cn进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 湖南方盛制药股份有限公司（以下简称"公司"）将于2025年10月24日发布公司2025年第三季度报告，为 便于广大投资者更全面深入地了解公司2025年第三季度经营成果、财务状况，公司计划于2025年10月24 日（星期五）09:00-10:00举行2025年第三季度业绩说明会，就投资者关心的问题进行交流。 关于召开2025年第三季度业绩说明会的公告 一、说明会类型 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 ...

Core Viewpoint - The Chinese medicine sector is experiencing a resurgence, with the Chinese Medicine ETF (560080) showing strong performance and attracting significant capital inflows, indicating investor confidence in the sector's recovery and growth potential [1][2]. Group 1: Market Performance - The Chinese Medicine ETF (560080) rose by 0.82%, marking a strong three-day upward trend, with a trading volume exceeding 120 million yuan on the day [1]. - The ETF has seen a net inflow of over 230 million yuan in the last ten days, bringing its total size to over 2.7 billion yuan, leading its peers significantly [1]. - Key constituent stocks such as Yiling Pharmaceutical and Darentang saw gains of over 5% and 4% respectively, while other stocks like Yunnan Baiyao and Pianzaihuang also experienced slight increases [1][4]. Group 2: Financing and Investment Trends - Leveraged funds are increasingly using the ETF to invest in the high-value Chinese medicine consumer sector, with the latest financing balance exceeding 82 million yuan, maintaining historical highs [2]. - The Chinese medicine sector is viewed as having a higher valuation attractiveness, with the ETF's price-to-earnings ratio at 25.37, positioned at the 24.65% percentile over the past decade [5]. Group 3: Policy and Industry Developments - Jiangxi Province has recently issued guidelines to enhance the quality of Chinese medicine and promote high-quality development in the industry, focusing on modernizing Chinese medicinal material breeding and resource protection [3]. - The industry is expected to see improvements in operational fundamentals as inventory levels normalize and external pressures ease, with a projected recovery in growth rates in the latter half of the year [7][8]. Group 4: Strategic Focus Areas - Analysts suggest focusing on three main lines within the Chinese medicine industry: price governance, consumption recovery, and state-owned enterprise reform, which are expected to drive growth and investment opportunities [9][10]. - The recovery of consumer demand, driven by macroeconomic improvements and an aging population, is anticipated to boost sales of consumer-oriented Chinese medicine products [10].

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-086 湖南方盛制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 24 日（星期五）09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 17 日（星期五）至 10 月 23 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 fs88997135@126.com、603998@fangsheng.com.cn 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 湖南方盛制药股份有限公司（以下简称"公司 ...

Group 1 - The China Traditional Chinese Medicine Index (930641) has increased by 0.61% as of October 16, 2025, with notable gains from companies such as Darentang (600329) up 4.09% and Yiling Pharmaceutical (002603) up 3.22% [1] - The National Medical Products Administration has released a draft for public consultation aimed at accelerating post-marketing research and evaluation of traditional Chinese medicine injections, with a goal of "actively evaluating some, mandating evaluations for others, and legally eliminating some" [1] - The market is expected to return to high-growth sectors as the third quarter earnings reports approach, with strong performance anticipated in medical devices and traditional Chinese medicine companies [2] Group 2 - The top ten weighted stocks in the China Traditional Chinese Medicine Index as of September 30, 2025, include Yunnan Baiyao (000538) and Pien Tze Huang (600436), collectively accounting for 55.08% of the index [3] - The current holding ratio of traditional Chinese medicine stocks is approximately 0.37%, the lowest historically, indicating a potential opportunity for reallocation in the sector [2] - The demand for over-the-counter traditional Chinese medicine products remains strong, with some products experiencing double-digit growth [2]

每经AI快讯，10月16日，中药板块震荡拉升，贵州百灵涨停，维康药业、达仁堂、方盛制药、盘龙药 业、沃华医药跟涨。 （文章来源：每日经济新闻） ...

南方财经10月16日电，中药板块震荡拉升，贵州百灵涨停，维康药业、达仁堂、方盛制药、盘龙药业、 沃华医药跟涨。 ...

Group 1: Market Overview - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index rose 1.73% to 13118.75, and the ChiNext Index increased by 2.36% to 3025.87, indicating a positive market trend [1][7] - The overall market saw a reduction in trading volume, with a total turnover of 20903.87 billion, down by 5061.99 billion from the previous trading day, reflecting a cautious sentiment among investors [7][10] Group 2: Economic Indicators - In the first three quarters, RMB loans increased by 14.75 trillion, with M2 growing by 8.4% year-on-year as of the end of September [15][16] - The Consumer Price Index (CPI) fell by 0.3% year-on-year in September, while the Producer Price Index (PPI) decreased by 2.3%, indicating deflationary pressures in the economy [19][21] Group 3: Industry Dynamics - ASML reported a net sales of 7.5 billion euros in Q3 2025, with a gross margin of 51.6%, driven by strong demand for extreme ultraviolet (EUV) lithography equipment [27][28] - IDC reported that global smartphone shipments reached 322.7 million units in Q3 2025, a year-on-year increase of 2.6%, driven by high-end market demand [29][30] Group 4: Company Updates - Mindray Medical (300760.SZ) plans to issue H shares and list on the Hong Kong Stock Exchange to enhance its international strategy and capital strength [31] - Haiguang Information (688041.SH) reported a revenue of 9.49 billion for the first three quarters of 2025, a year-on-year increase of 54.65% [33] - Tailin Microelectronics (688591.SH) expects a revenue of 766 million for the first three quarters of 2025, representing a 30% year-on-year growth [36]

Group 1: Drug Development Announcement - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., received the Clinical Trial Approval Notice for the drug RuLuGoli Tablets from the National Medical Products Administration [1][2] - RuLuGoli Tablets are a GnRH receptor antagonist intended for the treatment of advanced prostate cancer [2] - The cumulative R&D investment for this drug project is approximately 3.89 million yuan (unaudited) [3] Group 2: Market Situation - The original drug for RuLuGoli Tablets was developed by Takeda Pharmaceutical Company and was first approved for sale in Japan on January 8, 2019 [4] - As of the announcement date, RuLuGoli Tablets have not yet been launched in China, and no original or generic products have been approved for sale [4] - In 2023, the global sales amount for RuLuGoli Tablets reached approximately $29.96 million, with a year-on-year growth rate of 58.6% [4] Group 3: Approval Process - After receiving the Clinical Trial Approval Notice, the company must conduct and complete clinical trials and submit the application for product listing according to the relevant regulations [5] Group 4: Share Pledge Announcement - The controlling shareholder, Zhang Qinghua, completed the pledge of 35 million shares (7.97% of the total share capital) on October 15, 2025 [8][9] - As of the announcement date, Zhang Qinghua directly holds 156,019,500 shares, accounting for 35.53% of the total shares [8] - The pledged shares do not exceed 80% of the total shares held, indicating that the overall pledge risk is controllable [8][12]

Group 1: Company Announcements - Tianpu Co. announced that its stock will resume trading on October 16 after completing an investigation into unusual trading activity, with a significant price increase of 317.72% over 15 consecutive trading days [1] - Haiguang Information reported a third-quarter net profit of 760 million yuan, a year-on-year increase of 13.04%, driven by a 69.6% increase in revenue [1] - Tailing Microelectronics expects a net profit of approximately 140 million yuan for the first three quarters, a year-on-year increase of about 118%, supported by strong sales of new AI chips and other products [2] Group 2: Financial Performance - Guanghua Technology achieved a third-quarter net profit of 34.13 million yuan, a year-on-year increase of 962.19%, with total revenue of 762 million yuan, up 14.99% [3] - JiuZhou Pharmaceutical reported a third-quarter net profit growth of 42.3% [5] - HeSheng New Materials anticipates a net profit increase of 60% to 80% for the first three quarters [5] Group 3: Investment and Partnerships - China Ruilin plans to participate in establishing a mining fund with a total scale of 2 billion yuan, focusing on rare metals such as tungsten and rare earths [4] - Zhenyang Development signed a strategic cooperation framework agreement with Ningbo Graphene Innovation Center [7] - Liying Intelligent Manufacturing intends to increase investment in its subsidiary Vietnam Guanghong by 11.025 million USD [7]

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its generic drug, RuLuGoli Tablets [1] Group 1 - The approval is a significant milestone for the company's drug development efforts [1] - The clinical trial approval indicates progress in the company's research and development pipeline [1]